A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

830

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
SchizophreniaImpaired Cognition
Interventions
DRUG

EVP-6124

Arm 1, 2

Trial Locations (128)

Unknown

Little Rock

Anaheim

Bellflower

Cerritos

Chino

Costa Mesa

Culver City

Downey

Escondido

Garden Grove

Glendale

Los Angeles

Mesa

Norwalk

Oakland

Oceanside

Orange

Riverside

San Diego

San Gabriel

Santa Ana

Sherman Oaks

Torrance

Washington D.C.

Lauderhill

Miami

Miami Springs

North Miami

Oakland Park

Orange City

Orlando

Atlanta

Marietta

Smyrna

Chicago

Oak Brook

Oak Park

Wichita

Lake Charles

Shreveport

Boston

Minneapolis

Flowood

Creve Coeur

O'Fallon

Saint Charles

St Louis

Lincoln

Omaha

Nashua

Princeton

Albuquerque

Cedarhurst

Jamaica

New York

Charlotte

Cleveland

Shaker Hts.

Oklahoma City

Conshohocken

Jenkintown

Norristown

Philadelphia

Phoenixville

Austin

Dallas

Salt Lake City

Bellevue

Spokane

La Plata

Mendoza

C.a.b.a

Adelaide

Melbourne

Mechelen

Calgary

Penticton

Chatham

Kingston

Montreal

Medellín

Barranquilla

Pereira

Bogota D.C.

Bogota D.C

Berlin

Düsseldorf

Leipzig

Mittweida

Stralsund

Catania

Milan

Roma

Guadalajara

Mexico City

Monterrey

San Luis Potosí City

Mexico City

Bełchatów

Campulung Muscel

Oradea

Cluj-Napacu

Cluj-Napoca

Palazu Mare

Târgu Mureş

Bucharest

Talagi

Smolensk

Moscow

Saint Petersburg

Stavropol

Yaroslavl

Singapore

Salamanca

Zamora

Alcorcón

Coslada

Madrid

Vil. Stepanivka

Dnipropetrovsk

Ivano-Frankivsk

Kharkiv

Kyiv

Lviv

Poltara

Poltava

Vinnytsia

London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

FORUM Pharmaceuticals Inc

INDUSTRY